F M Investments LLC Purchases New Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX)

F M Investments LLC purchased a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 111,158 shares of the company's stock, valued at approximately $1,936,000. F M Investments LLC owned 0.14% of Travere Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. R Squared Ltd purchased a new position in Travere Therapeutics during the fourth quarter valued at approximately $53,000. Victory Capital Management Inc. purchased a new position in shares of Travere Therapeutics during the 4th quarter valued at $182,000. Baader Bank Aktiengesellschaft bought a new position in shares of Travere Therapeutics in the fourth quarter worth $192,000. Entropy Technologies LP purchased a new stake in shares of Travere Therapeutics in the fourth quarter worth $214,000. Finally, E Fund Management Co. Ltd. bought a new stake in Travere Therapeutics during the fourth quarter valued at $217,000.

Insider Activity

In related news, CAO Sandra Calvin sold 54,244 shares of the company's stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total transaction of $1,356,100.00. Following the completion of the sale, the chief accounting officer now directly owns 54,410 shares in the company, valued at $1,360,250. This represents a 49.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Eric M. Dube sold 50,691 shares of the firm's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $20.21, for a total transaction of $1,024,465.11. Following the completion of the sale, the chief executive officer now directly owns 430,548 shares in the company, valued at approximately $8,701,375.08. This trade represents a 10.53 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 188,877 shares of company stock valued at $4,147,627. 3.75% of the stock is currently owned by company insiders.

Remove Ads

Travere Therapeutics Trading Up 0.5 %

NASDAQ TVTX traded up $0.08 during trading on Tuesday, hitting $14.91. 1,364,016 shares of the company's stock traded hands, compared to its average volume of 1,517,782. The stock has a fifty day moving average of $19.47 and a two-hundred day moving average of $18.60. Travere Therapeutics, Inc. has a 12-month low of $5.12 and a 12-month high of $25.29. The firm has a market cap of $1.32 billion, a P/E ratio of -3.64 and a beta of 0.84. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.15). The company had revenue of $74.79 million for the quarter, compared to analysts' expectations of $72.38 million. Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. As a group, sell-side analysts expect that Travere Therapeutics, Inc. will post -1.4 EPS for the current year.

Wall Street Analysts Forecast Growth

TVTX has been the topic of several recent analyst reports. Scotiabank reaffirmed an "outperform" rating on shares of Travere Therapeutics in a report on Friday. JPMorgan Chase & Co. raised their target price on shares of Travere Therapeutics from $42.00 to $44.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Evercore ISI lifted their target price on shares of Travere Therapeutics from $33.00 to $45.00 and gave the company an "outperform" rating in a research report on Wednesday, February 12th. HC Wainwright increased their price target on shares of Travere Therapeutics from $18.00 to $22.00 and gave the stock a "buy" rating in a report on Wednesday, January 15th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Travere Therapeutics in a report on Thursday, April 3rd. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Travere Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $32.08.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.